ASCO Annual Meeting | Conference

Single Dose of Radiation as Effective as 5-Day Course for Maintaining Mobility in Patients with Spinal Cord Compression

June 3rd 2017

Results from a large, phase III trial showed that a single radiation treatment relieves symptoms of spinal cord compression in patients with advanced cancer as effectively as a multifractional course of radiotherapy (RT)

Fear of Recurrence and Anxiety Lowered in Cancer Survivors After Psychological Intervention

June 3rd 2017

Psychological intervention can substantially lower fear of cancer recurrence in survivors, improving their quality of life, anxiety, and cancer-specific distress, according to a phase II randomized clinical trial presented at the 2017 ASCO Annual Meeting.

Ribociclib Benefit in Breast Cancer Sustained With Longer Follow-Up

June 2nd 2017

Frontline treatment with ribociclib plus letrozole improved progression-free survival by 9.3 months compared with letrozole plus placebo for patients with postmenopausal HR-positive, HER2-negative advanced breast cancer.

ASCO 2017: Oncology Leaders Pick Their Top Abstracts

May 30th 2017

Key opinion leaders spoke with OncLive to share the top-5 abstracts they find to be the most exciting and/or potentially practice-changing across breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, hematologic malignancies, and supportive care being presented at the 2017 ASCO Annual Meeting.

Adjuvant Gefitinib Delays Recurrence in EGFR+ NSCLC

May 18th 2017

Adjuvant gefitinib reduced the risk of disease recurrence by 40% versus standard chemotherapy in patients with EGFR-positive non–small cell lung cancer, study reports.

Adopting Healthy Lifestyle Leads to Improved Overall Survival in Postsurgical Colon Cancer

May 18th 2017

Patients with stage III colorectal cancer who maintained a healthy body weight, engaged in regular physical activity, and adopted other healthy lifestyle behaviors experienced a 42% lower chance of death and a trend toward reduced cancer recurrence.

HPV Vaccine Reduced High-Risk Oral Infections by Nearly 90%, but Poor Uptake Limits Impact

May 18th 2017

The efficacy of the human papillomavirus vaccine continues to be impressive, with newly reported findings showing that it reduced the prevalence of high-risk oral HPV infections by 88% in young adults who had at least 1 dose of the vaccine; however, low vaccine uptake remains a concern.

Affordable Care Act Positively Affects Stage at Diagnosis

May 18th 2017

More Stage I cancers were diagnosed after the passage of the Affordable Care Act within five screenable disease types than were diagnosed before ACA implementation.

Eating Nuts After Colon Cancer Improves Survival and Lowers Recurrence Risk

May 18th 2017

Findings of a new prospective study suggest that eating tree nuts like almonds, walnuts, and pecans can improve overall survival and reduce the risk of recurrence in patients with colon cancer.

Adjuvant Capecitabine Improves Survival in Biliary Tract Cancer

May 17th 2017

Treatment with adjuvant capecitabine improved overall survival by 15 months compared with observation alone for patients with macroscopically resected biliary tract cancer, according to findings from the phase III BILCAP study released in advance of the 2017 ASCO Annual Meeting.

Dr. Tempero on the HALO 301 Trial for Pancreatic Cancer

September 29th 2016

Margaret A. Tempero, MD, director, Pancreas Center, University of California, San Francisco, discusses the HALO 301 trial, which is exploring the addition of PEGPH20 to gemcitabine and albumin-bound paclitaxel as a potential treatment for patients with pancreatic adenocarcinoma.

Dr. Reidy-Lagunes on Sequencing Therapies for Patients With NETs

September 28th 2016

Diane Reidy-Lagunes, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses sequencing various treatments for patients with neuroendocrine tumors (NETs).

Dr. Yao on Health-Related QOL in Patients With Neuroendocrine Tumors

September 28th 2016

James C. Yao, MD, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, discusses a study exploring health-related quality of life (QOL) in patients with neuroendocrine tumors (NETs).

Dr. Idos on Remaining Questions With Multiplex Panel Testing

September 28th 2016

Gregory E. Idos, MD, assistant professor of Clinical Medicine, Department of Surgery, Division of Colorectal Surgery, Keck School of Medicine of University of Southern California, sheds light on the remaining questions with multiplex panel testing as well as the cost effectiveness of it.

Next-Generation Sequencing Analysis of Circulating Tumor DNA

September 26th 2016

Oliver Zill, data scientist, Guardant Health, discusses the somatic genomic landscape of over 15,000 patients with advanced-stage cancer from clinical next-generation sequencing analysis of circulating tumor DNA.

Dr. Mehnert on Promising Biomarkers for Immunotherapy

September 26th 2016

Janice Mehnert, MD, medical oncologist, director, Phase I and Developmental Therapeutics Program, Rutgers Cancer Institute of New Jersey, discussing promising biomarkers for patients to receive immunotherapy across tumor types.

Dr. Strosberg on the Results of the NETTER-1 Trial

September 8th 2016

Jonathan Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the results of the NETTER-1 trial.

Dr. Donnellan on TFR in Patients With CML Treated With Nilotinib

September 7th 2016

William B. Donnellan, MD, investigator, Hematologic Malignancies, principal investigator, Sarah Cannon Research Institute, discusses preliminary results of the ENESTop study, which looked at treatment-free remission (TFR) in patients with chronic myeloid leukemia in chronic phase who were treated with second-line nilotinib (Tasigna).

Benefit of Maintenance Olaparib in Patients With Ovarian Cancer

August 25th 2016

Charlie Gourley, PhD, MBChB, chair and honorary consultant in Medical Oncology at Edinburgh Cancer Research Centre in the United Kingdom, discusses a study comparing the use of olaparib (Lynparza) after chemotherapy with placebo after chemotherapy in patients with platinum-sensitive ovarian cancer.

Dr. Gadgeel on Pembrolizumab/Chemo Combo in NSCLC

August 23rd 2016

Shirish Gadgeel, MD, medical oncologist, leader of the Thoracic Oncology Multidisciplinary Team at Karmanos Cancer Institute, Wayne State University, discusses the KEYNOTE-021 study, which is examining the combination of pembrolizumab (Keytruda) and chemotherapy as a potential treatment for patients with non–small cell lung cancer.